Juho Jalkanen

Juho Jalkanen

Company: Faron Pharmaceuticals

Job title: Chief Development Officer

Seminars:

Closing Panel: The Future of Innate Immune Checkpoints & Activation 2:30 pm

Delving into the horizons of homing of innate cells and reprograming of the tumor microenvironment Discussing novel checkpoint inhibitors Analysing the various immunotherapy approaches discussed & beyond Updates on clinical trials for immunotherapies In vitro models and discovery technologies for innate cell-based therapies New methodologies of analyzing innate immune cells in the tumor microenvironment (scRNAseq,…Read more

day: Innate Immune Checkpoints & Activation Pre-Focus Day

Igniting IFNg Responses to Overcome Resistance with a Novel Macrophage Checkpoint 2:00 pm

CLEVER-1 is a master immunosuppressive scavenger receptor on TAMs Bexmarilimab, a first in class anti-CLEVER-1 mAb, is the first macrophage checkpoint to show single agent activity in advanced solid tumors Bexmarilimab works by igniting IFNg responses where they do not exist, paving the road for classical checkpoint inhibitorsRead more

day: Innate Immune Checkpoints & Activation Pre-Focus Day

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.